Move to topTop
January 29, 2018

TOKYO, Japan -- January 29, 2018 -- Terumo Corporation (TSE: 4543) announced today that it integrated the Silicon Valley Lab research and development facilities, located in northern California in the United States, with, Kalila Medical, Inc., a subsidiary of Terumo Corporation, on January 10, 2018. Terumo moved both facilities to a new site, now called the Terumo Bay Area Innovation Lab. Over the next five years, plans call for the new lab to employ up to 50 people, about twice the current number.

Terumo established the Silicon Valley Lab in 2015. There, an R&D team transferred from Japan, along with some local personnel, primarily conducted early-stage research and development of products for the U.S. market. Kalila was a subsidiary that joined Terumo from Abbott Laboratories, a U.S-based company, in January 2017. Kalila developed products for use with ablation treatment systems. By integrating the two R&D facilities, Terumo aims to accelerate the launch of corporate R&D projects while expanding its lineup of steerable sheaths for use with ablation systems.

In addition to the new Terumo Bay Area Innovation Lab, Terumo has been taking advantage of the concentration of medical technologies in Silicon Valley to develop innovative medical devices. Terumo invested in a venture fund in 2013. Then, in 2014, it established a subsidiary, Terumo Medical Innovation Inc., to engage in development projects onsite at hospitals. By taking these steps, Terumo has positioned itself to explore new technologies and ideas while conducting early-stage product development.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.